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Abstract
Objective: To assess if a strategy of early ART to prevent HIV transmission is acceptable to ART naı¨ve people with HIV with
high CD4 counts.
Design: ASTRA is a UK multicentre, cross sectional study of 3258 HIV outpatients in 2011/12. A self-completed questionnaire
collected sociodemographic, behavioral and health data, and attitudes to ART; CD4 count was recorded from clinical
records.
Methods: ART naı¨ve participants with CD4 $350 cells/mL (n = 281) were asked to agree/disagree/undecided with the
statements (i) I would want to start treatment now if this would slightly reduce my risk of getting a serious illness, and (ii) I
would want to start treatment now if this would make me less infectious to a sexual partner, even if there was no benefit to
my own health.
Results: Participants were 85% MSM, 76% white, 11% women. Of 281 participants, 49.5% and 45.2% agreed they would start
ART for reasons (i) and (ii) respectively; 62.6% agreed with either (i) or (ii); 12.5% agreed with neither; 24.9% were uncertain.
Factors independently associated (p,0.1) with agreement to (i) were: lower CD4, more recent HIV diagnosis, physical
symptoms, not being depressed, greater financial hardship, and with agreement to (ii) were: being heterosexual, more
recent HIV diagnosis, being sexually active.
Conclusions: A strategy of starting ART at high CD4 counts is likely to be acceptable to the majority of HIV-diagnosed
individuals. Almost half with CD4 .350 would start ART to reduce infectiousness, even if treatment did not benefit their
own health. However a significant minority would not like to start ART either for modest health benefit or to reduce
infectivity. Any change in approach to ART initiation must take account of individual preferences. Transmission models of
potential benefit of early ART should consider that ART uptake may be lower than that seen with low CD4 counts.
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Introduction
Untreated HIV-infection causes progressive CD4 depletion and
increasing risk of AIDS-defining illnesses and death. It is
uncontroversial that antiretroviral treatment (ART) should be
started before immunosuppression is advanced and the risk of
serious illness becomes significant. However there is no clear
consensus regarding precisely when (at what CD4 count) an HIV-
infected person should start ART. In the current (2012) European
AIDs Clinical Society guidelines, commencement of ART is
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recommended with a CD4 count below 350 cells/mL [1]. With
asymptomatic HIV infection and a CD4 count between 350–500
cells/mL it is recommended that ART be considered, but deferred
at counts .500 cells/mL [1]. Similar recommendations on CD4
thresholds are made by the UK 2012 guidelines [2]. In July 2012,
WHO guidelines, which are influential for treatment programmes
in developing countries, recommended starting ART at a
threshold of 500 CD4 cells/mL [3]. In contrast, in 2012 the U.S.
Guideline Committee, the DHHS [4], and the IAS-USA [5],
recommended that ART be initiated in all people with HIV,
regardless of CD4 count. Recommendations to start at CD4
counts above 350 cells/mL are based on evidence from observa-
tional studies and trials with deferral strategies to start below 250
cells/mL, and remain controversial [6].
Randomized Control Trial (RCT) evidence of the clinical
effectiveness of starting ART (at higher CD4 counts) is currently
being evaluated in the START trial [7], an international trial that
has almost fully recruited 4600 participants and also in the
TEMPRANO trial [8] - now fully recruited with 1600 participants
in Coˆte D’Ivoire. In START, HIV-infected individuals with CD4
count.500 cells/mL are randomized to immediate ART initiation
or deferral until CD4 count has declined to 350 cells/mL. The
results of TEMPRANO are expected in 2015 and START in
2016. However, even if clinical benefit were shown in randomized
evaluation, the absolute risk reduction of ill health associated with
early ART is likely to be modest, given the low risk of serious
illness with CD4 counts .350 cells/mL [9].
However, the potential individual clinical benefit of earlier
treatment is not the only factor under consideration in the debate
regarding when people diagnosed with HIV should start ART.
There is increasing interest in a policy of early ART to reduce
HIV transmission. Observational studies report that people on
ART with a suppressed viral load have markedly reduced
infectiousness [10–12]. The HPTN 052 RCT prospectively
evaluated the effect of ART on prevention of HIV transmission
to HIV negative heterosexual partners. This study reported 96%
reduction of transmissions in serodifferent couples (CD4 count
350–550 cells/mL at entry) assigned to the early ART arm [13]
compared to those where ART was differed to CD4 count ,250
cells/mL. The results of this landmark trial in 2011 dramatically
increased interest in the use of ART for prevention. UK,
European, WHO and American guidelines now recommend
explaining to all HIV positive individuals that there is a beneficial
effect of ART on infectiousness and that ART be offered to
anyone who wants to take it to reduce transmission risk
[2,4,14,15].
The question arises as to whether a policy of ART for all people
diagnosed with HIV should be adopted, even in the absence of
evidence of significant individual health benefit.
There remain unanswered questions prior to widespread roll
out of ART for prevention of transmission for people with higher
CD4 counts. Issues include the durability of the prevention effect
and, especially in a non-trial setting, the lack of precise
transmission risk estimates for sex without the use of condoms
(particularly for anal sex), long term adherence and tolerability of
treatment, and the potential for transmission of resistant strains. In
addition there are issues in resource-restrained environments with
insufficient roll out of ART to those under 350 cells/mL [16]. One
of the most significant unknowns, however, is the extent to which a
policy of early ART would be acceptable to people with HIV,
particularly if there was little or no individual health benefit to
starting therapy at higher CD4 counts.
The aim of this study was to use data from the ASTRA
(Antiretroviral, Sexual Transmission Risk and Attitudes) UK
multi-centre questionnaire study of outpatients with HIV, to
investigate attitudes to earlier ART (i) for modest potential health
benefit, and (ii) to reduce infectiousness, among ART-naı¨ve HIV
diagnosed individuals with CD4 count $350cells/mL.
Methods
Ethics statement
Ethical approval for the ASTRA study was obtained via the
National Research Ethics Service (10/H0720/70).
ASTRA was a cross-sectional self-administered questionnaire
study in 3258 outpatients recruited from February 2011 to
December 2012 at eight UK outpatient HIV clinics. The overall
response rate was 64%. The questionnaire collected information
on demographic, social, lifestyle, HIV and health-related factors,
in addition to beliefs about sexual transmission risk, and attitudes
to early ART (for participants who were ART naı¨ve only). Most
recent CD4 count and viral load were recorded from clinical
records for all participants. In addition, 2983 (92%) of the 3258
participants gave consent for linkage of their questionnaire data
with routine clinical information from their HIV clinic records.
The full methods for the ASTRA study are published elsewhere
[17].
Of 3258 participants, 3202 gave information on ART status of
which 364 (11.4%) reported that they had never taken ART. Of
these 364, a further 6 participants were excluded as linked clinical
data recorded ART use at the time of the questionnaire. Of the
remaining 358 participants 281 had a CD4 cell count of $
350cells/mL (according to CD4 count recorded in the study log)
and are included in this analysis (8.6% of the total ASTRA
sample).
Participants who were ART naı¨ve were asked the extent to
which they agreed with the following statements: (i) I would want
to start treatment now if this would slightly reduce my risk of
getting a serious illness; (ii) I would want to start treatment now if
this would make me less infectious to a sexual partner, even if there
was no benefit to my own health
Response options were: strongly agree; tend to agree; undecided
or no opinion; tend to disagree; strongly disagree. Factors
associated with agreement (‘strongly agree’ or ‘tend to agree’,
versus all other responses) to statements (i) (starting for modest
health benefit) and (ii) (starting to reduce infectiousness) were
assessed.
Factors considered were demographic and social factors [age
group, gender/sexuality, ethnicity, country of birth, employment
status, education, financial hardship, current partner, children,
social support (assessed by a modified version of the Duke UNC
Functional Social Support Questionnaire [18]); HIV-related
factors [time since HIV diagnosis, latest CD4 count]; health-
related factors [hepatitis C diagnosis ever, recent diagnosed
sexually transmitted infection; depressive symptoms (‘major
depressive disorder’ according to PHQ-9 [19]; moderate or high
physical symptom distress (assessed by a modified version of the
Memorial Symptoms Assessment Scale Short-Form [20]); lifestyle
factors [smoking status, alcohol use (assessed by modified WHO
AUDIT-C questionnaire) and alcohol dependency (assessed by
CAGE questionnaire [21], recent recreational drug use]; recent
sexual activity; ART optimism (agreement with the statement
‘better HIV treatment means people are less worried about
infecting others’).
Chi-squared tests and chi-squared tests for trend were used to
assess the univariable associations of the above factors with
agreement to attitude questions (i) and (ii). Logistic regression
analysis was used to produce unadjusted odds ratios with 95%
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confidence intervals, and to assess multivariable associations. The
final multivariable models were developed as follows: first all
factors with p#0.1 in univariable associations were included in an
intermediate model; next each of the other factors was added to
the intermediate model individually, and retained if p#0.1.
Results are presented as adjusted odds ratios (OR) with 95%
confidence intervals. Likelihood ratio tests were used to produce p-
values. ART optimism variables were not considered as potential
factors to be included in the multivariable model as they were
considered too similar to the outcomes of interest (attitudes to early
ART).
Results
Overall, 281 ART naı¨ve participants were included in this
analysis (Table 1). Of these 85.0% were MSM, 3.9% heterosexual
men and 11.0% women. The mean age was 39.5 years (range 20
to 71 years). Ethnicity was 76.2% white, 8.5% Black African and
15.3% other ethnicity. CD4 count was 350–499 mm3, 500–
699 mm3 and $700 mm3 in 35.2%, 38.1% and 26.7% respec-
tively. Overall 74.4% were in employment and 46.3% university
educated. In terms of sufficient money to cover basic needs, less
than half (44.8%) reported always having sufficient money to cover
basic needs. Half (50.5%) had a stable partner of whom 47.2%
were also HIV positive. In terms of health behaviours; 43.4% were
current smokers, 24.2% had hazardous or harmful drinking on
CAGE screen and 53.0% had used recreational drugs in the
previous 3 months.
Figure 1 shows attitudes to starting early ART. A quarter
(25.3%) of participants strongly agreed that they would want to
start ART now to slightly reduce risk of serious illness, while a
similar number (24.2%) tended to agree with this statement. A
further quarter (25.3%) was undecided, and the remaining quarter
disagreed (tend to disagree 16%, strongly disagree: 9.3%). A
similar pattern of response was apparent for wanting to start ART
now to reduce infectiousness even if there was no health benefit,
although the proportions who were undecided was somewhat
higher (30.2%).
Combining the ‘strongly’ and ‘tend to’ responses, the percent-
ages of participants agreeing that they would want to start ART
now to: (i) slightly reduce risk of serious illness was 49.5% (139/
281) and (ii) to reduce infectiousness even if there was no health
benefit was 45.2% (127/281). Overall, 32.0% (90/281) of
participants agreed with both statements (i) and (ii), 30.6% (86/
291) agreed with one of the two statements, 12.5% (35/281)
disagreed with both statements, and 24.9% (70/281) were
uncertain.
Table 1 shows the unadjusted associations of agreement with
statements (i) and (ii) with other factors (demographic, socio-
economic, health-related, lifestyle, sexual activity and ART
optimism). In unadjusted analysis, ‘wanting to start ART for
modest health benefit’ was associated with being heterosexual
compared to MSM (p=0.080), greater levels of financial hardship
(p = 0.004, test for trend), low levels of social support (p = 0.017,
trend), having a lower CD4 count (p = 0.09, trend), shorter length
of time since HIV diagnosis (p = 0.019, trend), having moderate or
high physical symptom distress scores (p = 0.016) and agreeing that
ART meant people were less worried about infecting others
(p = 0.005). Univariable associations with starting ART for (ii) to
reduce infectiousness even if there was no health benefit were
being heterosexual compared to MSM (p= 0.092), shorter length
of time since HIV diagnosis (p = 0.001, trend), being sexually
active in the past 3 months (p = 0.056) and agreeing that ART
meant people were less worried about infecting others (p,0.001).
Among participants who were sexually active, there was no
evidence that the proportion wanting to start to reduce
infectiousness differed between those having condom-protected
compared to condom-less sex (Table 1).
Table 2 and 3 show factors included in the final multivariable
models for agreement with statements (i) and (ii). The ART
optimism variable was not included in these models. Factors that
remained independently associated (p,0.1) with wanting to start
ART for (i) modest health benefit were: having a lower CD4
count; a more recent HIV diagnosis; financial hardship; presence
of moderate or high physical symptom distress. In addition,
absence of major depressive disorder by PHQ-9 was significantly
associated with wanting to start ART for health benefit once the
other factors were included in the model. Factors independently
associated (p#0.1) with (ii) wanting to start ART to reduce
infectiousness even if there was no health benefit were: having a
more recent HIV diagnosis; being heterosexual compared to
MSM; being currently sexually active.
Discussion
This is the first study to our knowledge to assess the acceptability
of ART at high CD4 counts to reduce the risk of transmission to
others in people with HIV in a general clinic setting. We found
that almost one half (45%) of HIV-diagnosed individuals not on
ART with CD4 $350cells/mL reported that they would want to
start early ART to reduce infectiousness, even with no health
benefit and that half (50%) would want to start for modest health
benefit i.e. a small reduction in risk of serious illness. Overall,
62.6% would want to start ART for either or both reasons, 12.5%
indicated they would not want to start for either reason, while
24.9% were uncertain. People who had lived longer with HIV
were much less likely to want to start ART for either reason, and
those with higher CD4 counts were less likely to want to start for
modest health benefit.
There is now overwhelming evidence of the reduction in
infectiousness through heterosexual sex when the HIV positive
partner is on ART with a suppressed VL, although evidence for
reduction in infectiousness through anal sex is still lacking [22]. It
is therefore entirely appropriate that this should be explained to all
people with HIV and ART offered to those who wish to take it to
reduce infectiousness; a stance reflected in current guidelines in
this area [1,3,4,14]. It is, however, a different matter to advance a
general recommendation of ART for all those with diagnosed HIV
to prevent transmission as a public health measure. Indeed a key
factor in determining in the acceptability and therefore the success
of such a strategy of ‘ART for prevention of HIV transmission’
must be the willingness of people who are HIV positive to
voluntarily take ART at higher CD4 counts for what may be a
minimal absolute reduction in personal risk of adverse clinical
outcomes
It is also important to consider the generalizability of ‘when to
start’ RCTs which may show modest health gain. The success of
ART is highly dependent on readiness to start and motivation to
adhere to treatment. Trial participants are a selected group who
necessarily must agree in principle to randomisation to early
treatment, and may well have a preference for early ART, or high
motivation to adhere to ART. The promise of a slight health gain
may not universally be viewed by people who are HIV positive as
a sufficient incentive to start ART at high CD4 counts and
individual preferences and concerns need to be taken into account.
We found that those with high CD4 counts (.700 cells/mL)
were much less likely to want to start ART for a small reduction in
the risk of serious illness, most likely reflecting their perception of
Acceptability of ART at High CD4 Counts in ART Naı¨ve Individuals
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Table 1. Association of factors with (i) wanting to start ART for modest health benefit* and (ii) wanting to start ART to reduce
infectiousness* among 281 ART naı¨ve people with CD4$350/cells/mL.
N
n (%) who agree
with (i) would
start for modest
health benefit P value
n (%) who agree with (ii)
Would start to reduce
infectiousness P value
TOTAL 281 139 (49.5) 127 (45.2)
Gender/Sexuality group MSM 239 113 (47.3) 0.080 103 (43.1) 0.092
Heterosexual men and women 42 26 (61.9) 24 (57.1)
Ethnicity White 214 101 (47.2) 0.17 94 (43.9) 0.44
Black African/other ethnicity 67 38 (56.7) 33 (49.3)
Born in UK? Yes 170 80 (47.1) 0.48 77 (45.3) 0.82
No 107 55 (51.4) 47 (43.9)
Age group (Years) #30 44 19 (43.2) 0.64 21 (47.7) 0.88
30–50 196 100 (51.0) 90 (45.9)
.50 31 15 (48.4) 13 (41.9)
Employment Employed 209 98 (46.9) 0.14 93 (44.5) 0.69
Other 72 41 (56.9) 34 (47.2)
Education Uni education 130 65 (50.0) 0.78 62 (47.7) 0.42
Other 147 71 (48.3) 63 (42.9)
‘Money to cover basic needs?’
(financial hardship)
Yes, always 126 50 (39.7) 0.004 trend 53 (42.1) 0.22 trend
Yes, mostly 82 44 (53.7) 38 (46.3)
Yes, sometimes 43 24 (55.8) 18 (41.9)
No 27 18 (66.7) 16 (59.2)
Stable partner Yes, HIV +ve 67 33 (49.3) 0.19 25 (37.3) 0.30
Yes, HIV –ve 75 31 (41.3) 37 (49.3)
No partner 138 75 (54.3) 65 (47.1)
Have children Yes 43 26 (60.5) 0.12 22 (51.2) 0.41
No 237 113 (47.7) 105 (44.3)
Social support group (measure of
supportive relationships, modified
Duke UNC FSSQ)
1: High 79 31 (39.2) 0.017 trend 31 (39.2) 0.76 trend
2–4 171 89 (52.0) 85 (49.7)
5: Low 27 17 (63.0) 9 (33.3)
Time since HIV diagnosis #3 months 30 17 (56.7) 0.019 trend 14 (46.7) 0.001 trend
3 months–2 years 91 52 (57.1) 53 (58.2)
2–5 years 79 36 (45.6) 38 (48.1)
.5 years 78 31 (39.7) 21 (26.9)
CD4 count/cells/mL from clinic
records
350–499 99 54 (54.5) 0.090 trend 43 (43.4) 0.46 trend
500–699 107 54 (50.5) 47 (43.9)
$700 75 31 (41.3) 37 (49.3)
Smoking status Current 122 60 (49.2) 0.92 53 (43.4) 0.61
Ex 68 35 (51.5) 29 (42.6)
Never 91 44 (48.4) 45 (49.5)
Heavy drinking# (modified WHO
AUDIT-C)
No 247 124 (50.2) 0.51 108 (43.7) 0.18
Yes 34 15 (44.1) 19 (55.9)
Alcohol misuse (by CAGE) No 213 105 (49.3) 0.92 93 (43.7) 0.36
Yes 68 34 (50.0) 34 (50.0)
Recreational drug past 3 months No 132 62 (47.0) 0.43 56 (42.4) 0.38
Yes 149 77 (51.7) 71 (47.7)
Major depression symptoms (by
PHQ-9)
No 239 121 (50.6) 0.35 108 (45.2) 0.99
Acceptability of ART at High CD4 Counts in ART Naı¨ve Individuals
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their current low risk of such health problems. We also found a
strong association with financial hardship. People experiencing
greater levels of financial hardship were considerably more likely
to want to start ART for modest health benefit perhaps indicating
the vulnerability of their situation and the unwillingness to
consider even a small health risk due to the potential impact on
an already precarious financial situation. We also found that those
who scored higher for physical symptom distress were more likely
to wish to start ART for modest health benefit, which may indicate
optimism about the potential health benefits of ART, or that they
perceive that their current symptoms may be due to uncontrolled
HIV infection. Conversely participants who met criteria for major
Table 1. Cont.
N
n (%) who agree
with (i) would
start for modest
health benefit P value
n (%) who agree with (ii)
Would start to reduce
infectiousness P value
Yes 42 18 (42.9) 19 (45.2)
Moderate/high physical symptom
distress
$
(modified MSAS-SF
questionnaire)
No 239 111 (46.4) 0.016 109 (45.6) 0.74
Yes 42 28 (66.7) 18 (42.9)
Hepatitis C diagnosis ever No 254 127 (50.0) 0.58 118 (46.5) 0.19
Yes 27 12 (44.4) 9 (33.3)
STI in past 3 months No 237 115 (48.5) 0.46 106 (44.7) 0.71
Yes 44 24 (54.5) 21 (47.7)
Sexually active (vaginal/anal sex)
in past 3 months
No 61 28 (45.9) 0.53 21 (34.4) 0.056
Yes 220 111 (50.5) 106 (48.2)
Sexual activity category in past
3 months:
No vaginal/anal sex status
partner(s)
61 28 (45.9) 0.36 21 (34.4) 0.20
Condom-protected sex only 86 49 (57.0) 45 (52.3)
Condom-less sex HIV+ve
partners only
75 33 (44.0) 34 (45.3)
Condom-less sex HIV-ve or
unknown status partner(s)
51 24 (47.1) 23 (45.1)
Agree ART mean people less
worried infecting others
(ART optimism)
Yes 100 61 (61.0) 0.005 60 (60.0) ,0.001
No/unsure 175 76 (43.4) 64 (35.6)
* tend to agree or strongly agree combined, versus undecided/tend to disagree/strongly disagree combined.
P values by chi-squared tests, and chi-squared tests for trend.
#usual alcohol intake of at least 5 units 4 or more times a week, or at least 10 units 2–3 times a week.
$
score of 10 or more, based on total distress score for 19 physical symptoms, each scored 0 (symptom not present or no distress) to 4 (distressed very much by
symptom).
doi:10.1371/journal.pone.0097340.t001
Figure 1. Attitudes to early ART among 281 ART naı¨ve individuals with CD4 $350cells/mL.
doi:10.1371/journal.pone.0097340.g001
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Table 2. Independent association of factors with (i) wanting to start ART for modest health benefit* in ART naı¨ve people with CD4$350/cells/mL.
N n (%) who agree* P value
Unadjusted odds ratio
(95% CI)
Adjusted odds ratio
(95% CI) # (N=275)
P value for adjusted
model#
TOTAL 281 139 (49.5)
‘Money to cover basic needs?’(financial
hardship)
Yes, always 126 50 (39.7) 0.004 trend 1 1 0.007 trend
Yes, mostly 82 44 (53.7) 1.8 (1.0, 3.1) 1.8 (1.0, 3.3)
Yes, sometimes 43 24 (55.8) 1.9 (1.0, 3.9) 2.2 (1.0, 4.7)
No 27 18 (66.7) 3.0 (1.3, 7.3) 2.8 (1.1, 7.5)
Time since HIV diagnosis #3 months 30 17 (56.7) 0.019 trend 1.0 (0.4, 2.3) 0.8 (0.3, 2.0) 0.038 trend
3 months–2 years 91 52 (57.1) 1 1
2–5 years 79 36 (45.6) 0.6 (0.3, 1.2) 0.6 (0.3, 1.1)
.5 years 78 31 (39.7) 0.5 (0.3, 0.9) 0.4 (0.2, 0.8)
CD4 count cells/mL 350–499 99 54 (54.5) 0.090 trend 1 1 0.044 trend
500–699 107 54 (50.5) 0.8 (0.5, 1.5) 0.8 (0.4, 1.4)
$700 75 31 (41.3) 0.6 (0.3, 1.1) 0.5 (0.3, 1.0)
Major depression (PHQ-9 MDD) No 239 121 (50.6) 0.35 1 1 0.019
Yes 42 18 (42.9) 0.7 (0.4, 1.4) 0.4 (0.2, 0.9)
Moderate/high physical symptom distress
$
(modified MSAS questionnaire)
No 239 111 (46.4) 0.016 1 1 0.046
Yes 42 28 (66.7) 2.3 (1.2, 4.6) 2.3 (1.0, 5.1)
*tend to agree or strongly agree combined, versus undecided/tend to disagree/strongly disagree combined.
#using logistic regression analysis; p values by likelihood ratio test.
$
score of 10 or more, based on total distress score for 19 physical symptoms, each scored 0 (symptom not present or no distress) to 4 (distressed very much by symptom).
doi:10.1371/journal.pone.0097340.t002
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depressive symptoms were less likely to wish to start ART for
health benefit, perhaps indicating a reduced interest or concern in
their health, or lack of motivation to take regular medication or a
negative low mood meant that positive health or future benefits
did not resonate as important in their life choices.
People who had lived longer with diagnosed HIV were less
likely to want to start immediate ART, either for reasons of health
or reduced infectivity. Individuals who have lived longer with
untreated HIV and potentially through an era where early
treatment was not on the agenda and there was a great awareness
of drug toxicities, may perceive their current health status as good
without being on ART. The association with time since HIV
diagnosis was particularly strong for not wanting to start to reduce
infectiousness. Individuals with longstanding infections have had
years to assess issues of infectiousness and potentially adapt sexual
practices and other risks, so may be less interested in ART to
reduce infectiousness. Conversely individuals diagnosed recently
have been diagnosed in an era where early ART is very much on
the agenda, new treatments are safe and tolerable, and ART may
be generally more favourably perceived.
Modelling work to assess the impact of ART on population
transmission has considered issues such as adherence to ART and
sexual risk behaviour change on ART, but the potential lower
uptake of ART has not generally been considered, presumably
partly due to lack of data on the acceptability of taking ART to
individuals with high CD4 counts [23]. Our results are consistent
with the view that uptake and adherence might well be somewhat
lower if ART is initiated in people where there is not a clear and
immediate personal health risk.
One potential limitation of our study is that the study was
conducted only in UK HIV outpatients, and the majority of
participants were MSM. Results may not be generalizable to other
settings, in particular to resource-limited settings. We had limited
power to assess differences according to gender/transmission
group. Our data suggested demographic variation in likelihood of
wanting to start immediate ART, with some evidence that
heterosexual men and women were more likely to want to start
than MSM. However confidence intervals for this estimate were
wide. In addition, the views we are reporting were expressed in
2011/12 and we should consider that attitudes to early ART to
prevent transmission might change rapidly as the publicity around
treatment for prevention gains momentum. Likewise, results from
ongoing randomized trials could cause a further shift in views. In
addition, in this large quantitative study we were not able to
explore in depth motivations for responses to the questions
regarding early ART. Further qualitative research in this area
would be beneficial.
The only other data that we are aware of in this area is from the
HPTN 052 trial itself, which was conducted, largely in heterosex-
ual couples in 9 countries [13]. After the HPTN 052 study results
of 96% reduction in HIV transmission in the early treatment arm
were made public, ART was offered to all HIV positive
participants in the delayed arm. However, even with the
knowledge that ART had a dramatic effect on risk of transmission,
20% of participants in the deferred ART group - who had agreed
at study entry to possible randomisation to initiate ART at higher
CD4 count - chose not to initiate ART [24]. This indicates that
even in this highly select study population a significant proportion
of people feel reluctance to initiate ART primarily to prevent
transmission.
In conclusion, a strategy of starting ART at high CD4 counts is
likely to be acceptable to the majority of HIV-diagnosed
individuals. Nearly two thirds of ART naı¨ve respondents with
CD4.350/mm3 said they would start immediate ART either for
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modest health benefit or to reduce infectiousness and almost one
half would start to reduce infectiousness even if there were no
health benefits. Nonetheless, our results suggest that any change in
ART initiation must carefully consider individual needs and
preferences. It is unlikely to be universally acceptable to initiate
ART at a high CD4 count, even if modest health benefits become
established in randomized trials. This information on potential
uptake of earlier ART should be incorporated into transmission
models of the potential population benefit of early ART.
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